To the full analysis
Myriad Genetics stock: growth
MYGNMyriad Genetics reported $824.5M in revenue for fiscal 2025, down 1.6% on the prior year, up 5.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.6%
per year from 2006 to 2025, per share 8.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2019 | since 2014 | since 2006 | |
|---|---|---|---|
| Revenue | 5.2% | 1.3% | 9.6% |
| Revenue per share | 0.6% | −1.4% | 8.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $157.13M | −$34.96M | −$37.25M |
| 2007 | $222.86M | $47.85M | $90.06M |
| 2008 | $326.53M | $84.62M | $84.04M |
| 2009 | $362.65M | $152.3M | $147.19M |
| 2010 | $402.08M | $100.71M | $125.04M |
| 2011 | $496.01M | $112.15M | $131.65M |
| 2012 | $613.2M | $147.2M | $162.5M |
| 2013 | $778.2M | $176.2M | $175.9M |
| 2014 | $723.1M | $80.2M | $116.6M |
| 2015 | $740.5M | $117.2M | $161.3M |
| 2016 | $728.7M | $17.4M | $100.1M |
| 2017 | $743.7M | $133.3M | $107.5M |
| 2018 | $851.1M | $4.6M | $75.1M |
| 2019 | $638.6M | −$199.5M | $50.5M |
| 2021 | $690.6M | −$27.2M | $600K |
| 2022 | $678.4M | −$112M | −$151.6M |
| 2023 | $753.2M | −$263.3M | −$184.2M |
| 2024 | $837.6M | −$127.3M | −$38.4M |
| 2025 | $824.5M | −$365.9M | −$25.6M |
Revenue by region
Where Myriad Genetics, Inc. generates its revenue.
- United States93%
- Outside the US7%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $671.7M | $769.5M | $768M | 93.1% |
| Outside the US | $81.5M | $68.1M | $56.5M | 6.9% |
| Total revenue | $753.2M | $837.6M | $824.5M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.